[1] Nagata M, et, al. Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3285-E3294. DOI:
10.1073/pnas.1618133114[2] BARBARA KOVACIC. Glucosylceramide Critically Contributes to the Host Defense of Cystic Fibrosis Lungs.[J]. Cellular Physiology and Biochemistry, 2017, 41 3: 1208-1218. DOI:
10.1159/000464382[3] MICHELLE M MIELKE. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study.[J]. PLoS ONE, 2013: e73094. DOI:
10.1371/journal.pone.0073094[4] WILLIAM L HOLLAND Scott A S. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.[J]. Endocrine reviews, 2008, 29 4: 381-402. DOI:
10.1210/er.2007-0025